Level Four Advisory Services’s 10x Genomics TXG Stock Holding History

Level Four Advisory Services’s Portfolio TXG Stock Details TXG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.14M	Sell	29,637 -6,510	-18%	-$171K	0.03%	428
2026 Q1	$767K	Sell	36,147 -11,503	-24%	-$230K	0.03%	477
2025 Q4	$777K	Sell	47,650 -7,101	-13%	-$107K	0.03%	462
2025 Q3	$640K	Buy	+54,751	New	+$714K	0.02%	498

Other funds holding TXG

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

QCM

Quantinno Capital Management New York $83.3B AUM 37.97% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Level Four Advisory Services's TXG Position: Q2 2026 in Review

Level Four Advisory Services reduced its 10x Genomics (TXG) stake by 18% in Q2 2026, selling an estimated $171K and leaving 29,637 shares worth $1.14M. The position accounts for 0.03% of the portfolio, ranked #428.

Level Four Advisory Services first reported a position in TXG in Q3 2025 and has held it in 4 quarters since. 392 funds tracked by Wall St. Rank hold TXG as of Q2 2026.

Level Four Advisory Services held 29,637 shares of 10x Genomics worth $1.14M as of Q2 2026.
Level Four Advisory Services sold 6,510 10x Genomics shares in Q2 2026, an estimated $171K.
10x Genomics made up 0.03% of Level Four Advisory Services's portfolio in Q2 2026, its #428 holding.
Level Four Advisory Services first reported a position in 10x Genomics in Q3 2025 and has held it in 4 quarters since.
392 funds tracked by Wall St. Rank held 10x Genomics as of Q2 2026.

Based on Level Four Advisory Services's 13F filing for Q2 2026, filed 10 Aug 2026.